Risk of Allodynia with GLP-1 Agonists
Frey, C.; Sodhi, M.; Kezouh, A.; Etminan, M.
Show abstract
BackgroundGlucagon-like peptide-1 (GLP-1) receptor agonists, including liraglutide and semaglutide, are widely prescribed to treat type 2 diabetes mellitus and obesity. Recent anecdotal reports have suggested these agents might be associated with allodynia, a neuropathic pain syndrome, but large-scale epidemiologic evidence is lacking. MethodsTo investigate this potential link, a retrospective cohort study was conducted using the IQVIA PharMetrics(R) Plus database. Adults aged 18 and older who initiated liraglutide, semaglutide, or bupropion-naltrexone between 2006 and 2020 were included, excluding those with prior diabetes or antihyperglycemic therapy. Incident allodynia was identified via ICD-9/10 codes as the primary outcome. ResultsAmong 20,504 new users, those on GLP-1 receptor agonists had an allodynia incidence of 35 per 1,000 person-years, compared to 15 per 1,000 person-years for bupropion-naltrexone users. Adjusted analyses demonstrated over a twofold increased risk of allodynia with GLP-1 receptor agonists (aHR 2.15, 95% CI 1.57-2.96). ConclusionThese findings emphasize the need for heightened clinical vigilance and further research into mechanisms and management.
Matching journals
The top 4 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Clinical Characteristics Of Users Of Weight Loss Drugs: Population-Based Case-Control Study 91%
- Use of semaglutide and risk of non-arteritic anterior ischemic optic neuropathy: A Danish-Norwegian cohort study 91%
- Glucagon-like peptide-1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta-analysis and meta-regression 89%
Similar papers in this journal
- Cannabidivarin for the treatment of HIV-associated neuropathic pain: a randomized, blinded, controlled clinical trial 94%
- DrugWAS: Leveraging drug-wide association studies to facilitate drug repurposing for COVID-19 89%
- Role of Drugs used for chronic disease management on Susceptibility and Severity of COVID-19: A Large Case-Control Study 88%
Similar papers in this journal
- Declines, and Pronounced Regional Disparities, in Meperidine Use in the United States 90%
- Pharmacoepidemiology of Oxycodone in the USA: an observational study of ARCOS, Medicaid, and Medicare drug databases 89%
- Suspected Adverse Drug Reactions of the Type 2 Antidiabetic Drug Class Dipeptidyl-Peptidase IV inhibitors (DPP4i): Can polypharmacology help explain? 88%
Similar papers in this journal
- Savor the flavor — a randomized double-blind study on taste-enhanced placebo analgesia in healthy volunteers 90%
- Risk assessment of drug-induced Long QT Syndrome for some COVID-19 repurposed drugs 88%
- A long-acting GDF15 analog causes robust, sustained weight loss and reduction of food intake in an obese non-human primate model 88%
Similar papers in this journal
- The impact of sex and physical activity on the local immune response to muscle pain 90%
- Chemogenetic manipulation of microglia inhibits neuroinflammation and neuropathic pain in mice 88%
- Clenbuterol Attenuates Immune Reaction to Lipopolysaccharide and Its Relationship to Anhedonia in Adolescents 88%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.